Corcept names Justin Gunn to succeed retiring endocrinology president Sean Maduck

Corcept Therapeutics announced on September 23, 2026 that Sean Maduck, President of the company's Endocrinology division, is retiring¹. Justin Gunn will succeed Mr. Maduck and will fully assume his new responsibilities starting October 1.¹ Gunn will join Corcept's Executive Team and will report to Chief Executive Officer Joseph K. Belanoff.¹

According to the related 8-K, Maduck notified the company's Board of Directors on September 22, 2026 of his decision to resign, effective October 1, 2026.¹ The filing states that his departure was not tied to any internal dispute, noting Maduck's resignation was not due to any disagreement with the Company over its operations, financial statements, policies or practices.¹

To ease the handover, Maduck will stay on with Corcept as a senior commercial advisor.¹ Under a separate agreement, the company and Maduck signed a Consulting Services Agreement dated September 22, 2026 and effective October 1, 2026, running through an initial term ending September 30, 2027 unless ended earlier.¹ Maduck will receive $57,000 per month under the arrangement¹, and his existing stock options will keep vesting on their original schedule during the consulting period.¹ Either side can end the agreement with 30 days' written notice.¹

Gunn's background at Corcept includes joining in July 2024 as Vice President of Sales and Commercial Learning for the Oncology division, where he built a new field sales and training organization supporting the launch of Lifyorli, the company's treatment for platinum-resistant ovarian cancer used with nab-paclitaxel.¹ Earlier in his career, he spent nearly 18 years at Gilead Sciences across several therapeutic areas and held marketing and sales positions at Merck and Sepracor.¹ He holds a business administration degree from the University of Arkansas.¹